NCT05913752 - A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

May 1, 2025

Study Completion Date

October 1, 2025

Conditions

Alcohol Use Disorder

Interventions

DRUG

CMND-100

The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class

Trial Locations (3)

21224

Johns Hopkins Bayview Medical Center, Baltimore

526501

The Sophie and Abram Stuchynski Israeli Alzheimer Medical Center, Ramat Gan

06519

Connecticut Mental Health Center, New Haven